Blosozumab
From Infogalactic: the planetary knowledge core
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | SOST |
| Identifiers | |
| CAS Number | 1132758-87-2  |
| ATC code | none |
| KEGG | D10094 |
| Chemical data | |
| Formula | C6462H9852N1684O2030S46 |
| Molecular mass | 144.63 kg/mol |
 (what is this?) (verify) |
|
Blosozumab binds SOST, a negative regulator of osteoblast activity. Blocking SOST activity can lead to increased bone density.[1]
Blosozumab was developed by Eli Lilly and Company.
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it. |
Categories:
- Chemical articles having calculated molecular weight overwritten
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Monoclonal antibody stubs
- Musculoskeletal system drug stubs
- Eli Lilly and Company
